Venture Capital for Life Scientists, Chapter 1

The first installment of a 19 chapter textbook to help life scientists, founders, and investors work with and in venture capital focused on life science.

---

Venture Capital for Life Sciences is available on Amazon

---

About the Author

Dr. Will Alaynick is a scientist, entrepreneur, and investor dedicated to advancing life sciences through innovative ventures. With expertise in neuroscience and molecular endocrinology, he has conducted research in four Howard Hughes Medical Institute (HHMI) laboratories under the mentorship of four National Academy scientists. His academic contributions include more than 30 peer-reviewed publications in journals such as Cell, Science, and Neuron. Dr. Alaynick earned his PhD in Biomedical Sciences from the University of California, San Diego, conducting his doctoral and postdoctoral research at The Salk Institute for Biological Studies. He also holds a BA from the University of Washington in the History of Science, with honors coursework in organic chemistry and biochemistry.

Dr. Alaynick has founded and scaled multiple ventures bridging academic research and commercial success. As a co-founder of NanoCellect Biomedical and Arima Genomics, he led these companies from concept to global commercialization, securing significant funding through NIH grants, venture capital, strategic investments, and private equity. His expertise spans life science tools, reagents, medical devices, and molecular diagnostics.

Currently, as a managing partner at Phase Two Ventures, Dr. Alaynick focuses on early-stage investments in life science tools and technologies. His background as a scientist-turned-investor enables him to guide emerging companies, fostering scientific breakthroughs that translate into real-world impact​.

Introduction

Sometimes you are looking for a book and can’t find it, so I decided that the process of writing a book would help me understand the principles I wanted to learn—and help others in a similar position.

In theory, life is simple: do unto others as you would have them do unto you, eat a healthy diet, get plenty of zone two exercise, and get a good night’s sleep. But we find it is more complicated in practice. Business is simple, too: buy low, sell high. Here again, experience shows us that in theory, theory and practice are the same, but in practice, they are not.

As a scientist, founder, operator, and now investor, I have been trying to make sense and order out of what reality presents us. I began pursuing medicine before transitioning to basic research, specifically in the fields of developmental neurobiology and molecular endocrinology. Before working with top-tier HHMI and National Academy scientists and their teams, I have looked at situations in everyday life, healthcare, and scientific research and said to myself, “There must be a better way”. In retrospect maybe this is why I have been attracted to the study of science so I could understand the brass tacks of these problems

As a founder and operator, I’ve tried to apply this scientific approach to everyday problems. Founding companies like NanoCellect and Arima Genomics allowed me to take the principles learned in the lab and build companies that advance life sciences tools and technologies. Alongside co-founders and academic collaborators, I’ve tried to advance spinal cord rehabilitation, genomic analysis, and imaging flow cytometry. With NIH SBIR grants, venture investment, and strategic partnerships we scaled to make our dents in the universe. These experiences taught me that the complexities and tradeoffs of growing a business, managing teams, securing funding, and navigating regulatory pathways—all crucial elements of startup success.

Now, as an investor, I have the perspective of having lived at the intersection of science and business. My transition into venture capital has been driven by a desire to help other life scientists succeed in commercializing their breakthroughs. I understand the technical and scientific merits of early-stage ventures, but I also recognize the need for a solid business foundation. As a founder, I have walked the path that many startup teams are on today, and my goal is to offer not only financial support but also strategic guidance that can help accelerate innovation and transform industries. This book is part of that journey—aimed at providing life scientists with the tools, knowledge, and confidence to work with or in venture capital.

Will Alaynick, PhD

San Diego, CA 2025

Part 1: Foundations of Venture Capital in Life Sciences

Chapter 1: Introduction – Why Venture Capital Matters to Life Scientists

1.1. Defining Venture Capital in Life Sciences

Venture capital (VC) is a form of private equity financing in which specialized firms or funds invest in early-stage, high-potential companies in exchange for equity ownership. In the life sciences, VC provides critical funding for startups developing new therapies, medical devices, diagnostics, healthcare informatics, and contract research services that often require substantial capital before any revenue can be generated. Venture capital firms typically operate by raising a fund that pools money from limited partners (LPs) – such as pension funds, university endowments, or wealthy individuals – and then using that fund to invest in a portfolio of startups. The fund managers, known as general partners (GPs), make the investment decisions and actively manage the investments. A venture fund typically has a lifespan of about 10 years, aiming to deploy capital in the first few years and harvest returns as companies exit in later years. The economic model of VC funds often follows a “2-and-20” structure: an annual management fee (~2% of fund size) to cover operations, and a carry of ~20% of the profits from successful exits as the GPs’ performance incentive. This aligns the venture investors’ reward with the growth of the companies in which they invest.

Importantly, venture capital is distinct from traditional corporate R&D in that it enables independent new ventures to pursue innovative ideas outside the walls of established companies. Large pharmaceutical or medtech companies certainly invest heavily in R&D, but their internal projects often focus on incremental improvements or areas aligned with existing business. In contrast, VC-backed startups can pursue more radical or high-risk innovations that big companies might avoid. For example, in the early days of biotech, Genentech and others tackled recombinant DNA technology at a time when established pharma companies were skeptical of it. VC funding provided the freedom to explore these new scientific directions. Another difference is in control and governance: venture investors usually take a board seat and help steer the company. This means that venture-backed companies often have to balance scientific goals with business milestones set in agreement with their investors. Companies that can sure non-dilutive grant funding typically have more independence.

Finally, unlike bank loans or debt financing, which require assets (collateral) or revenue for repayment, venture capital accepts that early-stage life science companies have intangible assets (patents, data, talent) and possibly no revenue for years. Banks will not lend large sums to a preclinical drug startup with no cash flow, but VCs will invest equity and bear the risk of failure. In return, if the company succeeds, VCs own a portion of the company’s stock, which can appreciate dramatically. This equity-based risk sharing is a cornerstone of why VC is suited for life sciences: it matches the uncertain, long-term payoff profile of biotech innovation with patient capital willing to wait for a breakthrough

Table 1.1 Comparison of Life Science Funding Mechanisms. Venture capital involves equity investment and mentorship in exchange for potential high returns, whereas grants are non-dilutive and mission-driven. This is in contrast with angel investors that typically act individually at earlier stages. Corporate R&D is internally funded and often closely aligned with current goals. Corporate venture capital combines strategic and financial goals, but it still more closely aligned with corporate goals than VC. Venture debt provides loans to startups with some form of interest and an additional opportunity for gains through equity ownership. These mechanisms are often complementary and applied at different stages of the company’s growth – for instance, a biotech startup might begin with academic grants or seed funds, then attract angel investors, and later secure VC funding to advance through expensive clinical trials. These categories are not exact and there can be overlap and blending of certain aspects by individual organizations.

At a high level, VC funding ultimately plays a significant role in influencing the rate of new scientific advancements and products. In a typical year, the life sciences industry receives billions of dollars of venture capital. Large drops in life science VC funding (e.g., during the 2008–2009 recession and 2022-2024 Post-COVID downturn) have been associated with slowdowns in biotech innovation and job creation. In recent years, life science venture investment has grown dramatically – for example, U.S. healthcare and biotech startups raised record-high venture funding in 2021 (on the order of tens of billions of dollars in that year alone), reflecting both investor enthusiasm and the high capital needs of this sector. In short, venture capital is purpose-built to fund high-risk, high-reward endeavors, making it a crucial enabler for translating scientific breakthroughs into real-world innovations.

1.2. Historical Impact of Venture Capital on Biotechnology & Life Sciences

The modern biotechnology industry was born through partnerships between visionary scientists and venture capitalists in the 1970s. A seminal example is Genentech, founded in 1976 by UCSF professor Herbert Boyer and venture capitalist Robert Swanson. At the time, Boyer had co-developed recombinant DNA technology (gene splicing), and Swanson – a young partner at Kleiner Perkins – recognized its commercial potential. Genentech began with a modest $100,000 (~$550,000 in 2025) in seed funding from Kleiner Perkins, sealed by a famous handshake deal over a beer. This early VC backing enabled Boyer and a small team of young scientists to leave academia and prove that genetically engineered microbes could produce human proteins – a radical idea then. Their initial success was producing the peptide somatostatin in bacteria as a proof-of-concept in 1977, demonstrating that the science worked (somatostatin, while not a drug itself, was a relatively simple molecule and thus a good test case). From there, Genentech moved on to produce recombinant human insulin (in partnership with Eli Lilly) and human growth hormone (hGH) previously isolated from animals, validating that biotech startups could develop real therapeutics.

Venture capital financing was crucial at each stage of Genentech’s early growth. By 1980, only four years after founding, Genentech achieved a milestone as the first biotech company to go public. Its IPO, underwritten by Hambrecht & Quist, raised $35 million (~$135M in 2025), and the stock famously leapt from $35 to $88 per share in its first hour of trading. This 1980 Genentech IPO – valuing the young company at nearly $300 million (~$1.2B in 2025)– changed how people thought about public offerings in the context of high-tech and biotech ventures. It signaled that startup biotech firms, backed by venture funding, could tap public markets and attain substantial valuations even before turning a profit. The success spurred a flurry of investment into biotechnology: in the wake of Genentech’s IPO, numerous other biotech startups (often VC-funded) launched and sought their own funding. For example, Amgen (Applied Molecular Genetics) was founded in 1980 with backing from venture capitalists including William Bowes, who raised an initial $200,000 seed round from six VCs to start the company. Amgen went on to develop blockbuster biologic drugs like Epogen (for anemia) and Neupogen (for neutropenia), becoming one of the world’s largest biotech companies – a trajectory made possible by early VC funding and an IPO in 1983 that raised nearly $40 million. Similarly, Biogen was launched in 1978 by a group of prominent academic scientists (including MIT’s Phillip Sharp and Harvard’s Walter Gilbert) with initial venture financing; the company focused on interferon therapies and later moved its base to Cambridge, MA. Biogen’s academic founders lent tremendous scientific credibility, and VC support enabled its development of alpha interferon, one of the first biotech drugs to reach market in 1986 (licensed to Schering-Plough). Biogen went public in the 1980s and is today a leading biotech firm. These early successes (Genentech, Amgen, Biogen) proved that small, venture-funded companies could perform innovative drug research traditionally done in academia or big pharma—and deliver products to market. This laid the foundation for biotechnology as a viable investment sector and created an exciting new career path for scientists outside academia.

It is worth noting that not every early biotech followed Genentech’s trajectory; venture capital funded both successes and failures, which in turn provided learning and character building for the industry. One of the first biotechnology startups, Cetus Corporation, was founded in 1971 (five years before Genentech) with VC support and aimed to pioneer microbial engineering. Cetus scientists made significant advances – including developing the polymerase chain reaction (PCR) technique in the 1980s – yet the company struggled commercially. Cetus raised $108 million in an IPO in 1981 the largest biotech IPO to that date, but never achieved sustained profitability and eventually sold its key technology (the PCR process) to Roche in 1991 for a substantial sum. Cetus later merged into another venture-backed firm, Chiron Corporation. This case showed that even groundbreaking science (PCR earned a Nobel Prize for its inventor, Kerry Mullis) might not translate into a standalone company success without the right product focus. Venture capitalists learned from such outcomes, refining how they manage biotech ventures – for instance, ensuring startups have solid business fundamentals such as a clear therapeutic target or market application and not just great science.

Other early VC-backed biotechs included Chiron Corporation, as mentioned above, was founded 1981 and known for developing the first recombinant hepatitis B vaccine and was later acquired by Novartis. Another was Genex Corporation that was founded 1977 and focused on industrial enzymesand US. By the mid-1980s, dozens of biotech firms had been launched with venture funding, establishing biotechnology as a distinct sector. Notably, by the end of the 1980s, venture-backed biotech firms had produced recombinant human insulin (Genentech/Lilly, approved 1982), growth hormone, erythropoietin (Amgen’s Epogen “Epo”, 1989) and other innovations – achievements that required high-risk funding through years of unprofitable research and regulatory trials.

Venture capital not only provided capital but also business guidance in these early companies. In Genentech’s case, Kleiner Perkins partner Tom Perkins joined the board and helped pioneer a hybrid business model: rather than building a fully integrated pharmaceutical company, Genentech would conduct R&D and then partner with established pharma firms to underwrite expensive clinical trials and distribution in return for a share of profits. The first such arrangement was with Eli Lilly for human insulin, and it became a template repeated by many biotech startups. By 1990, Genentech had several marketed drugs and attracted majority ownership by Roche, which eventually acquired full control in 2009 at an implied valuation of approximately $100 billion.

Venture funding of biotech went global. Genzyme (founded 1981), developed treatments for rare genetic disorders, was a Boston-based startup that was acquired by Sanofi (a large French pharma) for $20B+. On the other hand, Biogen began in Geneva with European and US academics and VC, then expanded in the U.S. These illustrate how VC-backed biotechs eventually became major strategic assets for the global pharmaceutical industry early on.

In summary, the early decades of biotech (1970s–1980s) demonstrated venture capital’s catalytic role in translating breakthrough science into a new industry. Hundreds of millions of VC dollars were invested in an array of biotech startups, and while not all succeeded, those that did (Genentech, Amgen, Biogen, Genzyme, Chiron, etc.) revolutionized medicine. They proved that small ventures, when sufficiently funded and guided, could achieve what only big institutions had done before. This transformation set the stage for the explosion of biotech innovation in the ensuing decades, firmly establishing why venture capital is indispensable in life sciences.

1.3. Modern VC-Driven Breakthroughs in Life Sciences

Over the past two decades, venture capital has continued to fuel major breakthroughs across biotechnology and healthcare. One recent emblematic case is Moderna, a company at the forefront of mRNA therapeutics and vaccines. Moderna was founded in 2010 by Flagship Pioneering (a venture creation firm led by Noubar Afeyan) around the then-nascent idea of using messenger RNA to prompt the body to make its own medicines. In its early years, Moderna had no approved products and was essentially a platform research company – a profile often seen as too high-risk for traditional funding. Yet, venture capital enabled Moderna to grow aggressively: as a private company it raised over $2.7 billion in venture financing from Flagship and other investors, along with strategic investments from corporate partners like AstraZeneca. This massive VC commitment allowed Moderna to advance a broad pipeline of mRNA candidates and build manufacturing capabilities long before any revenue. The payoff came dramatically in 2020–21: when the COVID-19 pandemic struck, Moderna was able to rapidly pivot its platform to develop a vaccine. With an infusion of public funding for COVID vaccine research and its prior venture-backed groundwork, Moderna produced an effective mRNA vaccine in record time By late 2020, Moderna – barely a decade old and having been public for only two years – demonstrated Phase 3 clinical trial success (~94% efficacy) for its COVID-19 vaccine. Markets soared on the news, and Moderna’s swift response (relative to far larger pharmaceutical firms) highlighted how VC-backed agility can drive innovation. Moderna’s success propelled its market capitalization to around $39 billion by November 2020 (at ~$13 billion as of July 2025) vindicating the enormous upfront venture investment and establishing mRNA technology as a new pillar of medicine.

Another transformative area is CRISPR gene editing. The discovery of CRISPR-Cas9 around 2012 (by scientists Jennifer Doudna, Emmanuelle Charpentier, Feng Zhang and colleagues) quickly led to the formation of multiple startups aiming to harness this genome-editing tool for therapies. Venture capital poured into this field even as patent disputes were ongoing. In 2014–2015, a wave of investment established companies like Editas Medicine, Intellia Therapeutics, and CRISPR Therapeutics. In the span of 10 months during 2014–2015, over $280 million of venture funding flowed into CRISPR-focused startups. Editas Medicine, co-founded by Feng Zhang, raised a $43 million Series A led by Third Rock Ventures and others, and then a $120 million Series B in 2015 that drew in prominent investors including Fidelity and a fund backed by Bill Gates. This influx of capital – the largest financing for a CRISPR company at the time – gave Editas the resources to move gene-editing therapies toward clinical trials. By 2016, these companies were able to go public (Editas and Intellia each launched IPOs in 2016), illustrating how quickly VC can propel a revolutionary technology from lab to capital markets. Today, the CRISPR startups have multiple clinical trials underway. For example, CRISPR Therapeutics, in partnership with Vertex, secured FDA approval in 2023 for a CRISPR-based therapy for sickle cell disease, Casgevy (exagamglogene autotemcel) the first gene-editing therapy approved in the U.S. These advances would not have been possible without substantial early-stage venture funding to bridge the gap from basic science to viable drug programs. Investors essentially bet on the long-term potential of gene editing years before any human trial had begun, reflecting the venture community’s appetite for high-risk, high-impact science.

Venture capital has also driven progress in gene therapy, a field that languished for years due to scientific setbacks but saw a resurgence in the 2010s. For instance, Spark Therapeutics was founded in 2013 as a spin-out of Children’s Hospital of Philadelphia (CHOP) to commercialize a gene therapy for the treatment of patients with confirmed biallelic RPE65 mutation-associated retinal dystrophy. Spark raised about $50 million in initial venture financing and later additional rounds, enabling it to conduct pivotal trials for its treatment (voretigene neparvovec, marketed as Luxturna). In 2017 Luxturna became the first FDA-approved gene therapy for a genetic disease in the U.S. This validation led to Spark’s acquisition by Roche in 2019 for $4.8 billion – at that time the largest-ever venture-backed biotech exit in Philadelphia. The hospital, CHOP, that provided Spark’s seed funding reaped a return of about $430 million for its minority stake demonstrating the value that venture investment unlocked from an academic research program. Likewise, CAR-T cell therapy (engineered T cells to treat cancer) went from academic concept to approved treatment in under a decade thanks to VC-backed startups. Companies like Kite Pharma (founded 2009) and Juno Therapeutics (founded 2013) raised substantial venture funding to develop CAR-T therapies. Kite’s lead program led to FDA approval of Yescarta in 2017, shortly after which Kite was acquired by Gilead for $11.9 billion; Juno went public in 2014 and was acquired by Celgene in 2018 for $9 billion. These quick ascents – from university labs to multi-billion-dollar acquisitions – underscore how VC financing can accelerate development of entirely new treatment modalities.

Emerging technologies such as AI-driven drug discovery and personalized medicine have likewise attracted major venture capital commitments. Dozens of startups now apply artificial intelligence to drug design, and venture funding in this sector topped $10 billion globally between 2019 and 2022. For example, UK-based Exscientia raised a $225 million Series D in 2021 (along with additional equity commitments) to advance its AI platform for small-molecule drug discovery. Similarly, Insilico Medicine (with roots in the US and Hong Kong) secured $255 million in a 2021 Series C to push AI-designed drug candidates into the clinic. These financings, among the largest in the biotech AI space, reflect VC’s enthusiasm to fund platform technologies with long-term payoff. In healthcare informatics and digital health, ventures like Flatiron Health have shown how data-driven approaches attract both VC and strategic investors. Flatiron, founded in 2012 to aggregate real-world oncology data, raised a $130 million Series C led by Google Ventures in 2014. By 2018, Flatiron’s technology and value proposition led Roche (already a minority investor) to acquire the company for $1.9 billion yielding substantial returns to its VC backers. Similarly, telemedicine and health-tech companies (for example, Teladoc in telehealth, or Devoted Health in Medicare services) have attracted hundreds of millions in venture funding, seeking to transform healthcare delivery with technology.

Beyond healthcare, venture capital has driven synthetic biology – the engineering of organisms for purposes like sustainable materials, biofuels, or agriculture. A prominent example is Ginkgo Bioworks, founded in 2009 by MIT scientists to create a “biotech foundry” for designing microorganisms. Ginkgo struggled initially to convince investors due to its unconventional model, but eventually secured significant venture funding and grew rapidly. By 2019, it had raised over $700 million across multiple rounds, reaching a valuation above $4 billion as one of the first synthetic biology unicorns. In 2021, Ginkgo went public in a multi-billion-dollar SPAC deal, generating returns to investors and demonstrating how VC support over a decade enabled a new industry segment to emerge. While Ginko is down by more than half as of this writing, synthetic biology startups are still tackling everything from lab-grown meat to engineered microbes for agriculture, largely backed by venture capital. This highlights that life science VC isn’t confined to medicine – it extends broadly to life science innovation at the intersection of biology and technology.

Even traditionally service-oriented sectors, such as contract research organizations (CROs), have seen venture-backed innovation. A recent example is Vial, a San Francisco-based startup founded in 2020 aiming to radically streamline clinical trials with a tech-enabled CRO model. Despite being “just” a services business, Vial’s technology focus attracted VC interest; by 2022 it had secured over $100 million in financing (led by General Catalyst) to build its integrated e-clinical trial platforms This suggests that life science venture capital isn’t limited to drug or device invention – it also supports startups that innovate in how we conduct research and healthcare (through software, data, and new processes).

Across these examples – from gene editing to AI to novel healthcare services – venture capital’s role is evident: it provides the patient capital and strategic support needed to nurture high-risk ideas into tangible innovations. The common pattern is that VC enables a rapid scale-up (hiring scientists, running trials, building technology) that academic labs or small businesses could not achieve alone. Many of these VC-backed ventures also partner with or eventually get acquired by larger pharmaceutical and technology companies—innovation by acquisition—illustrating how VC serves as a bridge connecting early scientific insight to broad commercial impact.

Furthermore, the venture model has proven adaptable to many corners of life sciences. In the biopharmaceutical arena, small venture-backed companies are now a major source of new medicines – one analysis found that in 2020, early-stage, unprofitable or pre-revenue biotech companies were responsible for nearly 62% of FDA-approved new drugs and by 2022 about 65% of new drug approvals were attributed to emerging biopharma firms. This marks a significant shift: big pharma increasingly relies on innovation by acquisition: acquiring or licensing breakthroughs from VC-funded startups rather than originating all innovation internally. Venture capital is the engine enabling that shift by financing early drug development until it is attractive for larger players.

In addition to therapeutics, VC plays a key role in medical devices. For instance, Intuitive Surgical, a pioneer of robotic surgery, was a venture-backed startup founded in 1995 by physicians and engineers. It raised early venture rounds (from firms like Mayfield and Sierra Ventures) to develop what became the da Vinci Surgical System – now a globally adopted robotic surgery platform. Intuitive went public in 2000 and ultimately transformed surgical practice; its success has spawned an entire ecosystem of robotic and minimally invasive device startups, many VC-funded. Another device example is HeartFlow, founded in 2007 to develop AI-based cardiac imaging diagnostics. HeartFlow raised over $500 million from venture investors over a decade and successfully brought its non-invasive coronary artery disease test to market, illustrating VC’s role in medtech innovation as well.

In summary, modern venture capital has underwritten breakthroughs ranging from curing diseases with gene therapy and cell therapy, to harnessing AI for drug discovery, to improving how healthcare is delivered. The life sciences continue to be a high-risk arena, but venture funding has repeatedly shown it can convert risks into paradigm-shifting rewards – whether it’s a vaccine that changes the course of a pandemic or a new platform that reimagines an industry.

1.4. The Funding Gap – The “Valley of Death” in Life Sciences

While the success stories of VC-backed biotechs are impressive, many ventures, including Life Science ventures, struggle in the so-called “Valley of Death.” This phrase describes the perilous gap between early-stage research (often in academia or at the proof-of-concept stage) and the later stages of development where a product generates revenue. In this valley, a project is too applied or commercially oriented to continue receiving academic grants, yet too unproven or risky for significant private investment. The science may show promise (e.g., a new drug target validated in animal models or a novel medical device prototype), but additional funding is needed for activities like preclinical testing, process scale-up, or initial clinical trials – steps that don’t guarantee success but are necessary to attract major investors or industry partners.

The “Valley of Death” is especially acute in life sciences because of the long timelines and high costs before a product can be proven. A new therapeutic concept might require 5–10 years of work and tens of millions of dollars to reach a Phase I trial. Many investors are reluctant to fund projects at the very early preclinical stage due to the scientific uncertainty – as one report noted, “new ideas with commercial potential often do not attract sufficient private investment” because their value is not yet validated. This creates a Catch-22: without funding, the innovation cannot gather the data to prove its worth; yet without proof of concept, it cannot obtain funding. The result is that many academic discoveries stall after initial publications, never progressing toward a product.

Bridging this gap requires translational funding. Governments have tried to address it via grants like the Small Business Innovation Research (SBIR) program in the U.S., which since 1982 has provided seed grants to high-tech small businesses to advance U.S. innovation. SBIR grants provide “technically sound and commercially promising but unproven ideas” with early capital and a validation signal to the market. The term “Valley of Death” itself was used to describe this precarious transition period when an innovation is promising but too new to attract private capital. SBIR awards have been an important bridge: in 2007, for example, NIH and other agencies granted over $2.3 billion to small businesses through SBIR, compared to about $1.2 billion in seed-stage funding from private VCs that year. This illustrates how crucial public support can be when private capital is scarce. SBIR funding often works synergistically with angels and VCs – about 25% of top NIH Phase II SBIR awardees in 1992–2005 later secured venture funding, as the SBIR award provided validation and reduced risk.

Angel investors and foundations also play roles in the Valley of Death. Angels, often successful scientists or entrepreneurs themselves, may provide seed funding (e.g., $50k–$500k) to bridge an academic spin-out through proof-of-concept experiments. Disease-focused foundations sometimes offer grants or venture philanthropy investments—for instance, the Cystic Fibrosis Foundation’s early $150M program that helped Vertex develop breakthrough CF drugs including Kalydeco (ivacaftor) to push a therapy toward human trials—and led to the Cystic Fibrosis Foundation’s ~$5B in assets. Some government initiatives also specifically target this gap – for example, the California Institute for Regenerative Medicine (CIRM) has provided funding to stem cell startups at stages before private investors would. Moreover, universities have launched proof-of-concept funds or accelerators to help faculty commercialize promising research, offering modest funding and business mentoring to make projects more “VC-ready”. These efforts can help a nascent venture develop a prototype or gather preclinical data that will attract venture capital or corporate partnerships.

The Valley of Death concept has also prompted structural solutions. The U.S. National Institutes of Health established the National Center for Advancing Translational Sciences (NCATS) in 2011 specifically to address translational gaps – funding proof-of-concept studies, drug repurposing, and other bridge activities to ready projects for commercialization. Several countries have launched public-private partnership funds to invest in early-stage biotech (for example, the UK’s Biomedical Catalyst program and Germany’s High-Tech Gründerfonds) with the goal of de-risking academic innovations. Universities too have set up translational research accelerators: for instance, Harvard’s Blavatnik Biomedical Accelerator provides seed grants and business development support to faculty projects to help them reach milestones that attract venture investment. These efforts aim to de-risk projects just enough so that either venture capital or corporate R&D partners will pick them up.

Despite these initiatives, the transition from academia to startup remains challenging. Many scientists find that they must shift from a grant-driven mindset to an entrepreneurial one – focusing on clear milestones, intellectual property strategy, and product development plans. This is where understanding venture capital becomes important even before one seeks VC money. By aligning a project early on with metrics that investors care about (such as demonstrating a functional prototype or robust preclinical efficacy), a scientist can increase the chances that their project will survive the Valley of Death. We will explore in later chapters strategies for doing so, such as designing lean proof-of-concept experiments and engaging mentors or advisors from industry to guide a project’s translational strategy

.

Ultimately, venture capital is often the critical ingredient to cross the Valley of Death. A common pattern is as follows. An academic lab produces a discovery, a paper, and perhaps a patent; they receive a small SBIR grant or university seed fund to start a company; this gets the concept to a milestone (for example, a drug candidate showing efficacy in an animal model). At that point, a venture capital syndicate might step in to fund the more expensive development steps. VCs look for such “de-risked” opportunities where some groundwork is laid by non-dilutive funding. Reflecting this, angel investors sometimes view SBIR grants as enabling a company to develop to a stage where risk is sufficiently reduced to justify angel or VC investment Still, many projects do not make it through this gauntlet. This reality underscores why life scientists need to understand venture capital: to strategically align their work with the expectations of investors, to pursue alternative funding bridges when needed, and to increase the odds that their innovations can cross from lab to market.

1.5. The Venture Capital Model & Portfolio Approach in Life Sciences

Venture capital operates on a portfolio model: a VC fund will invest in a dozen or more companies with the expectation that only a few will achieve extraordinary success, while the rest underperform or fail This is often described as the power law of returns – the idea that a small number of investments drive the majority of profits—essentially spreading their bets. Life sciences VC is no exception; in fact, the model may be even more pronounced due to the binary nature of drug development outcomes (a drug either eventually gets approved and becomes valuable, or it fails in trials and the company’s value collapses). VCs mitigate this risk by constructing portfolios and by staging investments over multiple rounds. They typically provide funding in tranches tied to milestones (e.g., “we will invest $X now, and another $Y when you achieve Milestone A, such as IND clearance or Phase I data”). If milestones are met, the company can raise the next round (often with pro rata, or proportionate, participation from existing investors to maintain their stake). If not, the startup may be unable to secure further funding and will wind down. This high-attrition environment is anticipated in the VC model – successful funds make their returns from a minority of companies that achieve an exit (IPO or acquisition) at a valuation many times higher than the initial investment. An investment can only go down to zero—a 1X loss—but the potential returns can be 10X or greater.

Life sciences vs. tech portfolios: Life science startups generally face longer development timelines and heavier regulatory oversight than software or consumer tech startups. A new app or enterprise software might reach market and revenue within 1–2 years of seed funding; by contrast, a new drug often requires 5–7 years just to reach a Phase II trial, and perhaps 10+ years to achieve FDA approval. Consequently, life science VCs must be prepared to support companies for a longer haul and often with larger total investments. One outcome is that biotech venture rounds tend to be sizable – it’s not uncommon for a biotech to raise a $50–100 million Series A or B if expensive clinical trials are ahead. Another difference is the regulatory risk: FDA approval (or other regulatory clearance for devices/diagnostics) can be a make-or-break event. Tech VCs worry about product-market fit and competition, but biotech VCs also must bet on scientific validity and successful navigation of complex regulatory pathways. Because of these challenges, life science investors often focus or specialize in specific domains (e.g., oncology, neurology, gene therapy, digital health) where they have expertise and can better judge the science and regulatory requirements. Many venture firms in this sector hire MDs or PhDs as partners or bring on experienced biotech executives who have “been over the mountain” as venture advisors, to inform their decisions.

These factors influence the return profile for life sciences VC. Historically, biotech investments take longer to “exit” (reach IPO or acquisition) than tech investments, but when they hit, the payouts can be very large (blockbuster drugs can generate billions in annual sales). One counterbalancing feature is that promising biotechs can sometimes go public earlier in their lifecycle – even before product approval – if they can excite public investors with their science and team. In fact, in the last decade, many biotech IPOs have occurred when companies are in Phase I or II trials (pre-revenue), supported by compelling early data and the credibility of their VC backers. This path has been aided by crossover investors – hedge funds and other public-market investors who “crossover” into late private rounds. A crossover round is a late-stage private financing (usually 6–12 months before an IPO) in which there is significant participation from investors that typically invest in public companies Their involvement sends a strong signal and helps a biotech go public with a solid base of support. For example, out of 94 therapeutics-focused biotech IPOs from 2013 to 2014, about 26% had a crossover-led financing round beforehand. Presence of crossover investors has been correlated with successful IPOs and post-IPO share performance. In the frothy biotech market of 2020–2021, crossover rounds became almost a de facto step before IPO, involving firms like Wellington, BlackRock, and Deerfield investing in private biotechs to position them for the IPO pop.

Life science VCs often syndicate investments – meaning multiple VC firms jointly invest in a single round. Syndication allows sharing of the financial burden and risk of a company’s large capital needs, and it brings complementary expertise to the table (one investor might have deep immunotherapy know-how, another strength in scaling companies, for example). It’s not unusual for a biotech startup to have 3–5 venture firms as co-investors by the time it reaches a Series B or C round. These investors will coordinate their support and sometimes take turns as the lead investor in successive rounds. A lead investor typically negotiates the terms on behalf of the syndicate and often contributes the largest check in that round.

Exits (the way VCs realize returns) in life sciences often come via one of two routes: acquisition by a strategic incumbent or an IPO. Acquisitions can happen at various stages – some startups are bought in preclinical or Phase I stages if their technology is highly promising (big pharma might acquire to secure a platform early), whereas others are acquired after Phase II or III trial success to bolster a pharma’s pipeline. IPOs allow a company to tap public investors for (sometimes) even larger sums; interestingly, biotech IPOs frequently occur at an earlier stage than tech IPOs. It’s common for a biotech with no product revenue (and sometimes just initial human data) to go public, something rarely seen in other sectors. This is possible because specialized public investors are willing to value the future potential of a drug pipeline, and venture backers plus crossover investors effectively “market” the science to Wall Street. For example, Moderna’s IPO in 2018 occurred while most of its programs were still in Phase I, yet it raised over $600 million because investors believed in the platform and the venture support behind it. This interplay between private and public markets – VCs nurturing a company to the point where public investors take interest – is a defining feature of life sciences venture capital.

Another dynamic in the life sciences VC model is the competition for capital with other sectors. During economic downturns or periods of tech-sector fervor, some generalist investors shift money toward faster-return areas like software. The late 2000s provided a cautionary example: after the 2008 financial crisis, life science VC funding dropped significantly as firms retrenched, and more capital flowed into internet and tech deals. Life science ventures, which often require high funding levels, and the average time to a return on an investment can be long – especially compared to the tech sector, saw capital move away, as many have noted. Over time, this can be detrimental to biomedical innovation. Recognizing this, various policy makers and industry leaders have called for measures to incentivize life science investing (such as R&D tax credits or public-private co-investment programs). Nevertheless, dedicated biotech VC firms have persisted and even expanded because the potential rewards – a successful new drug or medical technology – can be enormous. The period from roughly 2010 to 2021 saw a renaissance in biotech investing: venture funding in biotech set new records each year, with U.S. biotech companies raising over $80 billion in venture capital in 2021 alone (amid a broader VC boom).

Life science VCs also increasingly collaborate with corporate venture capital arms of pharma/tech companies. Corporate VCs now regularly co-invest in rounds, providing ‘front row seats’ to strategic insight and often an inside track to a future acquisition or partnership. The presence of corporate venture investment can be a double-edged sword (it brings validation and resources but might deter that corporation’s rivals from partnering with the startup), yet it has become a common feature in the funding landscape.

To contextualize the industry impact: by the early 2020s, a significant proportion of pharmaceutical pipelines originated from companies that began as VC-funded startups. Large pharmaceutical companies routinely monitor the startup landscape for innovation and many have their own corporate venture funds to get early access to promising programs. In 2022, emerging biopharma companies (most venture-backed) were responsible for roughly two-thirds of new drug approvals This statistic emphasizes that the VC model – despite its high failure rate – is effective at yielding real products over time when viewed across an entire portfolio and industry.

One financing tool worth noting is venture debt, which some life science startups use to supplement equity funding. Venture debt providers (specialized banks or funds) offer loans to startups, typically after a VC equity round when the company has raised some capital and achieved milestones. In biotech, venture debt is often used by companies in mid-stages (e.g. after Phase I or II) that need extra cash between equity raises. The debt is usually secured by the company’s assets (often its intellectual property) and typically comes with warrants (options for the lender to buy equity) as part of the return. While not a replacement for equity – since loans must be repaid – venture debt can extend a startup’s cash runway with less dilution to founders and VCs. However, it adds fixed repayment obligations and other covenants, so it’s used cautiously in biotech where revenue may be years away. The venture investors and management must weigh the trade-off: if the science fails, debt can worsen the outcome by leaving the company owing money; but if used prudently, it can fund critical activities (e.g. a manufacturing scale-up or an additional trial arm) that increase the company’s value before the next equity event.

In summary, the venture model in life sciences accepts that most experiments will fail, but the few that succeed can change medicine and yield outsized returns. Venture capitalists thus structure their portfolios and financing terms (e.g., staged financing, syndication, reserving funds for follow-ons, engaging crossovers for IPO prep) to maximize the chances of capturing a big win. For scientist-entrepreneurs, this means that VCs will push for clear milestones and will not hesitate to cut losses on projects that aren’t meeting benchmarks. It also means that if you are the breakout success in a VC portfolio, the investors will double down to accelerate that success (for instance, leading larger follow-on rounds or recruiting top talent to your team—perhaps to replace you). Understanding this mentality – high tolerance for failure, but relentless focus on the slim chance of massive success – is important for life scientists who engage with venture funding.

1.6. Stakeholders & Roadmap for This Book

This introductory chapter sets the stage for Venture Capital for Life Scientists, a book tailored to a diverse audience of readers who intersect with science and venture investing. The primary audiences include:

• Academic scientists – graduate students, postdoctoral fellows, and professors – who are curious about how to translate laboratory discoveries into startups or who seek funding beyond traditional grants.

• Entrepreneurs and startup founders in the biomedical field, who may come from a science background and need to learn the mechanics of working with venture capitalists (from pitching and term sheets to scaling a company).

• Professionals considering careers in venture capital – e.g., a PhD in biology exploring a path into venture investing, or a pharma scientist/analyst aiming to specialize in healthcare venture funding.

• Industry stakeholders such as pharmaceutical or medtech executives, and service providers (lawyers, consultants, tech transfer officers) who want a deeper understanding of the venture financing process in life sciences.

• Limited Partners – investors who have an interest in venture capital in life sciences that can also align with mission-based investing to advance biomedical research.

Different chapters in this book address these groups and the various ways scientists and venture capital intersect. We will explore how to work with VCs – for instance, what a scientist-turned-founder needs to know about seeking investment and partnering with a venture firm (covering topics like pitching, due diligence, term sheets, intellectual property strategy, and building a board of directors). We will also discuss how to work for a VC – shedding light on roles for scientists within venture funds (analyst, associate, entrepreneur-in-residence, etc.), how to transition from the bench to investing, and the skills required to thrive in a venture career. For readers interested in launching investment vehicles, we examine how to start a venture fund or incubator, including raising capital from limited partners and assembling a team with both scientific and financial expertise. And for those who may want to invest in venture-backed science themselves (for example, as angel investors or limited partners in venture funds), the book provides context on evaluating opportunities and understanding venture portfolios

.

This book is organized to address these topics in depth. Part I provides an overview of venture capital mechanics – outlining how venture funds operate, how they evaluate opportunities, and key concepts (valuation, equity sharing, deal structuring) that any founder or employee should know. Part II focuses on working with venture capital from the entrepreneur’s perspective: how life science innovators can attract VC funding, build a startup team, protect their inventions, and navigate the stages of growth with their investors. Part III turns to careers in venture capital for scientists (“working for a VC”). It discusses pathways for advanced-degree holders to enter the venture industry, common roles (from junior analyst to partner), and expectations in those roles. We include insights from life scientists who successfully transitioned into venture roles. Finally, Part IV looks at broader perspectives – including how to start or join a venture fund (for those inclined to the investment side), how corporate venture funds operate and collaborate with startups, and considerations for scientists who might become investors themselves (for instance, by doing angel investing or contributing to venture funds). Throughout the book, we also consider the impact of venture capital on the future of research and innovation – essentially tying together how working with, *working for, starting, or investing in a venture capital firm can shape scientific careers and the trajectory of biomedical progress.

By the end of the book, a reader should be conversant in the language of venture capital and armed with a framework to navigate it. Whether your goal is to secure funding for a new venture, evaluate a job offer at a startup, or pivot into a venture career, the chapters ahead aim to provide guidance grounded in real-world examples and data.

1.7. Case Study: How a Scientist-Founded Startup Secured VC Investment

To illustrate the journey from scientific discovery to a venture-backed startup, let’s examine the early story of Editas Medicine, one of the first companies founded to develop CRISPR gene-editing therapies. Editas was formed in late 2013 by a group of leading scientists and entrepreneurs, including Dr. Feng Zhang of the Broad Institute of MIT/Harvard (a key contributor to CRISPR-Cas9 technology) and Dr. J. Keith Joung of Harvard/MGH, along with venture investors from Third Rock Ventures, Polaris Partners, and Flagship Ventures. The scientific founding team had made breakthrough discoveries in how CRISPR-Cas9 could be used to cut DNA at targeted sites – a technique with potential to treat genetic diseases by correcting mutations. However, turning this Nobel Prize-worthy science into a therapeutic product required far more than academic prowess; it needed a company with significant funding, infrastructure, and a development plan.

Recognizing this, the founders sought venture capital early. In 2014, Editas announced a Series A financing of $43 million, led by Third Rock Ventures (a life sciences-focused VC firm known for hands-on company formation) and joined by Flagship and Polaris. This initial round provided the capital to incorporate the company, hire a core team, secure laboratory space, and begin preclinical experiments on CRISPR-based therapies. Notably, Editas’s investors also brought in seasoned leadership – for example, Katrine Bosley, a biotech industry veteran, was recruited as CEO. This illustrates how VCs often help build the management team needed to complement the scientific founders.

With the Series A funds, Editas focused on a lead program: a CRISPR therapy for a rare genetic form of blindness (Leber congenital amaurosis type 10, or LCA10). The goal was to use CRISPR to excise a specific disease-causing mutation in patients’ retinal cells. By mid-2015, the company had shown encouraging preclinical results in animal models, enough to attract a second, much larger round of funding. In August 2015, Editas closed an oversubscribed Series B financing of $120 million, one of the largest private biotech raises that year. This round was noteworthy not only for its size but for the breadth of investors: it included not just traditional VCs but also crossover investors such as Fidelity and Casdin Capital, as well as Gates Ventures (Bill Gates’s investment arm). Such a syndicate signaled strong validation of Editas’s approach and the excitement around CRISPR. The influx of capital enabled the startup to accelerate IND-enabling studies (safety/toxicity studies needed before trials) and to scale up its operations significantly. Indeed, by securing this funding, Editas was effectively positioned for an IPO – the participation of crossover investors suggested an initial public offering was planned once sufficient progress had been made.

True to plan, Editas Medicine went public on the NASDAQ in February 2016, just a little over two years from its founding. The IPO raised roughly $94 million, and Third Rock and other early investors retained significant equity in the now-public company. Going public provided Editas with a more substantial war chest (hundreds of millions) to fund clinical trials. In 2020, Editas Medicine, in collaboration with Allergan, dosed the first patient in the U.S. with their CRISPR-based therapy, EDIT-101, targeting Leber congenital amaurosis 10 (LCA10) – notably, the first time CRISPR was used directly inside the human body in a clinical trial for an inherited disease.

It is important to acknowledge that the story is still unfolding – as of 2025, Editas has yet to bring a therapy to market, and the company’s stock price has seen volatility as initial excitement gave way to the realities of clinical development. The venture investors, however, had planned for a long journey; they raised additional funding for the company after the IPO (through follow-on offerings) and even brought in strategic partners to support development. Editas’ collaborations with Allergan (a leader in ophthalmology) and with Celgene (in oncology, to apply CRISPR to T cell therapies), developed deals that provided upfront payments and expertise. The initial partnership with Juno Therapeutics in 2015 to apply CRISPR to CAR-T cancer immunotherapy was another strategic move linking two VC-funded ventures showing the network effects in the ecosystem. These partnerships, common for VC-backed biotechs, further validate the technology while sharing the enormous costs of clinical trials. Venture backers often encourage such alliances because they can de-risk the startup’s path (for example, a large partner might bankroll a costly Phase I/II trial in exchange for commercialization rights).

From the perspective of the scientist-founders like Dr. Zhang and Dr. Joung, partnering with venture capitalists was a means to translate their discovery into something tangible for patients. It required some loss of control – bringing in professional executives and sharing decision-making with investors on the board – but it also brought the means to pursue ambitious goals. Without VC funding, it is unlikely a university lab alone could have conducted clinical-grade manufacturing of CRISPR reagents or run human trials on its own. Editas’s early trajectory – from academic insight to a public company treating patients in about 6–7 years (which is quite fast) – exemplifies what is possible when scientists engage with venture capital.

For scientist-founders, several takeaways emerge from this case: (1) Assemble a strong syndicate – having reputable VCs and crossover investors on board not only provides capital but also lends credibility and can attract further funding and talent; (2) Be prepared for management changes – investors may bring in professional management (as happened with Editas hiring an experienced CEO) and that can be positive for scaling the company; (3) Focus on clear, achievable targets – turning a broad technology (like CRISPR) into a pipeline of specific product candidates is crucial for convincing investors and partners of value. Editas chose an inherited retinal disease as a starting point, which was strategic because the eye is an organ with privileged immunity, is amenable to local treatment, and the clinical endpoint (improved vision) was well-defined. An early win in such a focused application helps justify the platform’s potential in other areas.

It’s also worth noting that scientist-founders have various ways to engage with their venture-backed startups. Some choose to take executive roles (e.g., Chief Scientific Officer) or even become the CEO, while others prefer to serve on the scientific advisory board and let experienced industry leaders run day-to-day operations. There is no single formula – for example, Dr. Herb Boyer took a hands-off role at Genentech after co-founding it (staying in academia and advising the company), whereas Dr. George Rathmann, Amgen’s first CEO, was a scientist-turned-executive who led Amgen through its early years. The key is that venture capital provides the resources to assemble a team that complements the founders’ skills. In Editas’s case, the founding scientists remained scientific advisors while the VC-recruited CEO and team handled execution. The takeaway is that venture investors will help recruit talent – business leaders, clinicians, regulatory experts – so that the founding scientists can focus on what they do best. Ultimately, what matters is assembling an effective team that can translate the science into a product and navigate business challenges, and VC funding gives the flexibility to build that team.

This case study of Editas Medicine demonstrates how a cutting-edge scientific discovery was bridged into clinical development via venture capital. It also highlights challenges: the company had to contend with intense patent disputes (between the Broad Institute and UC Berkeley groups over CRISPR IP) and must still prove its therapies are safe and effective in larger trials. But without VC involvement, CRISPR might have remained a laboratory tool for far longer, instead of rapidly moving toward therapeutic use. Many of the other CRISPR startups (Intellia, CRISPR Therapeutics) followed a similar playbook: enlist top scientists, secure strong VC syndicates, focus on one disease at a time, and go public to access the capital needed for clinical trials. The Editas story thus encapsulates why venture capital matters to life scientists – it can take a discovery that is “on the shelf” and give it the opportunity, funding, and structure to potentially become a new medicine.

1.8. Conclusion: The Need for Scientists to Engage with Venture Capital

Life science innovation has always been driven by scientific creativity, but bringing innovations to patients and the market requires more than brilliant ideas – it requires financing, strategy, and execution. Venture capital has proven to be a critical enabler in this process. As we have seen, entire industries like biotechnology were catalyzed by venture funding that took risks on unproven ideas like recombinant DNA or mRNA vaccines. The partnership between scientists and venture investors is, at its best, a symbiotic one: scientists provide novel ideas and deep expertise, while VCs provide the capital, business acumen, and risk tolerance needed to push those ideas forward.

For today’s life scientists, understanding the principles of venture capital is increasingly indispensable. If you are a researcher aiming to commercialize a discovery, knowing how to secure and work with VC funding can determine whether your innovation ever leaves the lab. Even if one’s goal is not to become an entrepreneur, scientists often interact with the startup ecosystem – for instance, via collaborations with biotech startups or by serving as scientific advisors. Familiarity with how venture-backed startups operate (their timelines, constraints, and goals) will improve these interactions. It enables scientists to better design experiments that address not only scientific questions but also translational milestones that investors or partners care about.

Moreover, a career in venture capital or entrepreneurship is an exciting alternative for those with scientific training. As the case studies illustrated, scientists have been founders (e.g., Herb Boyer of Genentech co-founded the company based on his academic work; Jennifer Doudna’s CRISPR science underpins Intellia) and also key drivers within venture firms (there are PhD-trained venture capital partners who shape investment in new technologies). Engaging with venture capital doesn't mean abandoning science; rather, it can be a way to amplify the impact of one’s scientific expertise. By translating discoveries into companies, scientist-entrepreneurs can directly contribute to developing new treatments and technologies for patients, fulfilling the societal promise of their research. At the same time, venture investors rely on scientifically literate professionals to evaluate cutting-edge ideas – creating opportunities for scientists to contribute on the investment side.

One should also recognize the broader societal implications: venture-backed life science innovations don’t just create financial returns; they create health benefits. The COVID-19 vaccine effort is a prime example – decades of venture investment in mRNA and related technologies enabled a rapid pandemic response that saved millions of lives. In cancer, venture-backed immunotherapy startups have brought forward cures for previously untreatable cancers. Thus, venture capital in life sciences can be seen as a mechanism by which society allocates capital to its most speculative but potentially transformative ideas in health. For scientists motivated by improving human health, engaging with this mechanism can greatly amplify the real-world reach of their work, taking it from an academic journal page to a therapy in the clinic.

At the same time, scientists should approach venture opportunities with open eyes. Not every research finding is suited for a startup or needs to be commercialized – some advances are better disseminated via academic channels or developed with public/nonprofit funding, especially if the market incentive is low (for instance, for certain neglected diseases). But for those discoveries that can lead to new products (drugs, diagnostics, devices, platform technologies), venture capital is often the only funding source capable of supporting the long, risky development process. Government grants typically taper off as projects become more product-driven, and large companies often prefer to wait until proof-of-concept is achieved before they invest heavily. The onus falls on startups and their investors to carry the baton in that interim. By learning about venture capital, scientists can better discern which path to take for their own innovations and can collaborate more effectively with the business side of biotech when the time comes.

In closing, venture capital matters to life scientists because it is often the vehicle that turns scientific possibility into reality. It provides the means to traverse the risky path from an idea to a life-saving product. By demystifying how VC works and fostering mutual understanding between scientists and investors, we can accelerate innovation to the benefit of society. We encourage readers – particularly those with scientific backgrounds – to approach this intersection with optimism and openness—despite being an ‘alternate career’ in the sciences. The coming chapters aim to equip you with knowledge and tools so that you can confidently engage with venture capital, whether you seek funding, plan to work in a startup, or consider a role in investment. Venture capital and life sciences need each other: one provides the spark of discovery, the other the fuel to ignite it. By understanding both, you can better ensure that great ideas in the lab become real-world solutions that improve health.

The following chapters will delve deeper into the practical aspects of this journey, equipping life scientists with the insight to navigate – and even lead – the exciting interface of science and venture capital.

1.9 References and Further Reading

1. Sahlman, W. A. (1990). The structure and governance of venture-capital organizations. Journal of Financial Economics, 27(2), 473–521. https://doi.org/10.1016/0304-405X(90)90065-8.

2. Kortum, S., & Lerner, J. (2000). Assessing the contribution of venture capital to innovation. RAND Journal of Economics, 31(4), 674–692. https://doi.org/10.2307/2696354.

3. Kerr, W. R., & Nanda, R. (2015). Financing innovation. Annual Review of Financial Economics, 7, 445–462. https://doi.org/10.1146/annurev-financial-111914-041825.

4. Ewens, M., Nanda, R., & Rhodes-Kropf, M. (2018). Cost of experimentation and the evolution of venture capital. Journal of Financial Economics, 128(3), 422–442. https://doi.org/10.1016/j.jfineco.2018.03.001.

5. Zucker, L. G., Darby, M. R., & Brewer, M. B. (1998). Intellectual human capital and the birth of U.S. biotechnology enterprises. American Economic Review, 88(1), 290–306.

6. Pisano, G. P. (2006). Science Business: The Promise, the Reality, and the Future of Biotech. Boston, MA: Harvard Business School Press. ISBN 978-1591398400.

7. Metrick, A., & Yasuda, A. (2021). Venture Capital and the Finance of Innovation (3rd ed.). Hoboken, NJ: Wiley. Print ISBN 978-1119490111.

8. Pammolli, F., Magazzini, L., & Riccaboni, M. (2011). The productivity crisis in pharmaceutical R&D. Nature Reviews Drug Discovery, 10(6), 428–438. https://doi.org/10.1038/nrd3405.

9. Darrow, J. J., Avorn, J., & Kesselheim, A. S. (2020). FDA approval and regulation of pharmaceuticals, 1983–2018. JAMA, 323(2), 164–176. https://doi.org/10.1001/jama.2019.20288.

© 2025 William Alaynick, PhD

All Rights Reserved

PHASE TWO PRESS